Latest news with #VISTA
Hi Dubai
02-07-2025
- Business
- Hi Dubai
Dubai Airshow Opens Registration for Most Ambitious Edition Yet
Registration is now open for the 19th edition of the Dubai Airshow, set to take place from November 17 to 21 at Dubai World Central, promising a future-focused platform for global aviation and defence leaders. The 2025 edition aims to drive innovation, strengthen cross-sector collaboration, and spotlight the UAE's growing role in the global aerospace arena. Organisers say this year's show will be the most comprehensive to date, aligning with the nation's vision to remain at the forefront of aviation advancement. The airshow comes as the UAE's aviation sector continues rapid growth, contributing $92 billion to GDP, according to the International Air Transport Association. The Middle East's commercial aircraft fleet is also projected to expand at 5.1% annually over the next decade. New additions to the show include a first-of-its-kind runway networking event at SkyDive Dubai and night-time programming with drone displays, music, and extended access to static aircraft exhibitions. Sustainability, future technologies, and talent development will remain key pillars of the programme. Flagship initiatives such as VISTA, the NextGen Leaders programme, and the new Academy will support start-ups and emerging professionals in aviation and space. Meanwhile, an AI-powered matchmaking tool will help streamline networking among delegates and decision-makers. With over 15,000 visitors expected at the public Skyview platform and a full agenda of curated forums, the 2025 Dubai Airshow is set to reaffirm its status as one of the world's most influential aviation events. News Source: Emirates News Agency
Dubai Eye
02-07-2025
- Business
- Dubai Eye
Dubai Airshow unveils main agenda with night events, runway networking
Dubai Airshow has officially opened registration for its 19th edition, taking place from November 17-21 at Dubai World Central. The event promises to be a game-changer for the aviation sector, spotlighting innovation, connectivity and future technologies. This year's show will feature new experiences, including the first-ever night-time programming and a unique runway networking event at SkyDive Dubai, blending industry engagement with entertainment such as drone shows, skydiving performances and live music. Major General Dr. Mubarak Saeed bin Ghafan Al Jabri, Executive Director of the Military Committee organising the event, said the Airshow will showcase the UAE's growing leadership in aviation and defence, while supporting the next generation of talent and innovation. The 2025 edition will also highlight sustainability, with a focus on environmentally friendly solutions and cross-sector collaboration. Key features returning include VISTA, the hub for aviation and space start-ups, the NextGen Leaders programme, and the newly launched Academy for emerging talent. According to the International Air Transport Association (IATA), aviation contributes $92 billion to the UAE's GDP - 18.2 per cent of the total - with the Middle East's commercial aircraft fleet expected to grow by 5.1 per cent annually over the next decade. Dubai Airshow will host senior executives through the Aerospace Executive Club and offer curated networking via an AI-powered matchmaking system. The public will also have access to Skyview, featuring live flying displays and interactive experiences, expected to attract over 15,000 visitors.
Daily Tribune
01-07-2025
- Business
- Daily Tribune
Dubai Airshow 2025 Set to Be the Biggest Yet
SK Dubai Airshow is coming back from 17 to 21 November 2025 at Dubai World Central (DWC), and it promises to be the biggest and most exciting edition so far. Registration is now open for this major global event in aerospace and defence. This year's show will focus on innovation, networking, and future technologies, with new features and experiences for professionals and the public. The event reflects the UAE's growing role in global aviation, with the sector contributing $92 billion to the country's GDP and strong growth expected in the region's aircraft fleet over the next decade. Key Highlights of Dubai Airshow 2025: Bigger and more immersive than ever before, with new zones and interactive displays. A platform for global industry leaders to connect, showcase tech, and shape the future. Skyview, the public area, will welcome over 15,000 visitors with airshows, workshops, and entertainment. Educational activities will inspire students and young people, including talks with pilots and astronauts. Tim Hawes, Managing Director at Informa Markets, said this year's show will be more future-focused and engaging, helping businesses connect and young talent grow. The event will support government strategies and spotlight areas like sustainability, innovation, and youth empowerment. Special New Experiences: Party on the Runway at SkyDive Dubai – a unique evening with drone shows, skydiving, music, and networking. Airshow After Dark – the show stays open late on day two for extra time to explore and enjoy evening events. The return of VISTA, the startup hub for aerospace innovation, and the NextGen Leaders programme to train and mentor new talent.
Associated Press
26-06-2025
- Business
- Associated Press
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales. HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026. 'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.' 'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.' About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system. About Hummingbird Bioscience Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact [email protected]. Hummingbird Bioscience Media Contact: Crystal Ho [email protected] [email protected] +65 6979 5580 Hummingbird Bioscience Investor Contact: [email protected]
Business Upturn
26-06-2025
- Business
- Business Upturn
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026 SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales. HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026. 'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.' 'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.' About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system. About Hummingbird Bioscience Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact [email protected]. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
